- Home
- PINE vs EYPT Comparison
PINE vs EYPT Comparison
Compare PINE & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PINE | EYPT |
|---|---|---|
| Founded | 2019 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Laboratory Analytical Instruments |
| Sector | Real Estate | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 317.1M | 273.3M |
| IPO Year | 2019 | 2005 |
Fundamental Metrics
Financial Performance| Metric | PINE | EYPT |
|---|---|---|
| Price | $16.64 | $0.36 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 13 |
| Target Price | ★ $19.90 | $8.44 |
| AVG Volume (30 Days) | 184.4K | ★ 16.2M |
| Earning Date | 10-22-2026 | 11-12-2026 |
| Dividend Yield | ★ 7.68% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $60,532,000.00 | $7,539,000.00 |
| Revenue This Year | $31.91 | N/A |
| Revenue Next Year | $10.40 | $126.05 |
| P/E Ratio | $40.21 | ★ N/A |
| Revenue Growth | ★ 15.90 | N/A |
| 52 Week Low | $15.29 | $0.34 |
| 52 Week High | $21.99 | $19.11 |
Technical Indicators
Market Signals| Indicator | PINE | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 42.58 | 16.83 |
| Support Level | $16.62 | N/A |
| Resistance Level | $19.93 | $3.57 |
| Average True Range (ATR) | 0.63 | 0.04 |
| MACD | 0.03 | 0.10 |
| Stochastic Oscillator | 37.48 | 14.18 |
Price Performance
Historical ComparisonAbout PINE Alpine Income Property Trust Inc.
Alpine Income Property Trust Inc is a real estate investment trust (REIT) that owns and operates a high-quality portfolio of commercial net lease properties in the United States. The company's portfolio predominantly comprises single-tenant retail properties located in or near metropolitan statistical areas, or MSAs. It operates in two business segments: income properties, which derive maximum revenue, and commercial loans and investments.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.